What do I need to know about the new RSV vaccine?
You might have seen the news earlier this month: the U.S. has approved the first vaccine for respiratory syncytial virus (RSV), for use in adults age 60 and older.

One dose of the vaccine Arexvy, from drugmaker GSK, was found to be nearly 83 per cent effective at preventing RSV lung infections in a study published in The New England Journal of Medicine.

It has taken decades of research to get to this point. During a disastrous clinical trial for a potential RSV vaccine for children in the 1960s, 80 per cent of children given the shot were hospitalized and two toddlers died.